ATE78262T1 - Hybrid-interferone. - Google Patents

Hybrid-interferone.

Info

Publication number
ATE78262T1
ATE78262T1 AT86810243T AT86810243T ATE78262T1 AT E78262 T1 ATE78262 T1 AT E78262T1 AT 86810243 T AT86810243 T AT 86810243T AT 86810243 T AT86810243 T AT 86810243T AT E78262 T1 ATE78262 T1 AT E78262T1
Authority
AT
Austria
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
AT86810243T
Other languages
English (en)
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus G Gruetter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE78262T1 publication Critical patent/ATE78262T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
AT86810243T 1985-06-11 1986-06-05 Hybrid-interferone. ATE78262T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
EP86810243A EP0205404B1 (de) 1985-06-11 1986-06-05 Hybrid-Interferone

Publications (1)

Publication Number Publication Date
ATE78262T1 true ATE78262T1 (de) 1992-08-15

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86810243T ATE78262T1 (de) 1985-06-11 1986-06-05 Hybrid-interferone.

Country Status (20)

Country Link
US (2) US4885166A (de)
EP (1) EP0205404B1 (de)
JP (2) JPH0655759B2 (de)
KR (1) KR920002267B1 (de)
AT (1) ATE78262T1 (de)
AU (1) AU598196B2 (de)
CA (1) CA1285507C (de)
CY (1) CY1842A (de)
DE (1) DE3685996T2 (de)
DK (1) DK168794B1 (de)
FI (1) FI90983C (de)
GR (1) GR861497B (de)
HK (1) HK99895A (de)
HU (1) HU203255B (de)
IE (1) IE57865B1 (de)
IL (1) IL79085A (de)
NO (1) NO175602C (de)
NZ (1) NZ216485A (de)
PT (1) PT82736B (de)
SG (1) SG25195G (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
CA2089553C (en) * 1990-08-29 2000-06-27 Paul Schendel Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DK0548012T3 (da) * 1991-12-16 1998-04-14 Ciba Geigy Ag Endoplasmatisk reticulum-placeret rekombinant dibasisk endoprotease samt dens anvendelse
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
WO1993018139A1 (en) * 1992-03-10 1993-09-16 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
TW218846B (de) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (de) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
EP0801682B1 (de) 1995-02-09 2001-10-24 Novartis AG Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
SG110047A1 (en) 1998-10-16 2005-04-28 Biogen Inc Polymer conjugates of interferon beta-a1 and uses
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
CN100420482C (zh) * 2000-11-03 2008-09-24 精达制药公司 ω干扰素在制备用于治疗丙型肝炎的药物中的用途
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2504267A1 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TW200611910A (en) * 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1888633A4 (de) * 2005-05-18 2010-01-27 Maxygen Inc Entfaltete interferon-alpha-polypeptide
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
EP2634243B1 (de) 2006-07-14 2017-09-06 Patheon Holdings I B.V. Verbessertes verfahren zur zellkultivierung
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
US20100143373A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Methods of treating systemic lupus erythematosus
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008137838A2 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
EP2219452B1 (de) 2007-11-05 2015-10-14 MedImmune, LLC Verfahren zur behandlung von skleroderm
SG188147A1 (en) 2008-02-08 2013-03-28 Medimmune Llc Disease markers and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2010289383B2 (en) 2009-09-03 2015-04-16 Medimmune, Llc Type 1 interferon diagnostic
ES2650667T3 (es) 2009-09-28 2018-01-19 Intarcia Therapeutics, Inc Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX359947B (es) 2011-03-15 2018-10-17 Biogen Ma Inc EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN113508138A (zh) 2019-02-15 2021-10-15 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032134B2 (de) * 1980-01-08 1993-10-13 Biogen, Inc. DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem menschlichen Interferon-alpha ähnlichen Polypeptiden
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (de) * 1982-01-19 1984-01-25 Cetus Corporation Hybrid-interferone verschiedener klassen
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone

Also Published As

Publication number Publication date
KR920002267B1 (ko) 1992-03-20
CY1842A (en) 1996-03-08
IL79085A (en) 1992-03-29
FI862461A (fi) 1986-12-12
HK99895A (en) 1995-06-30
FI90983C (fi) 1994-04-25
PT82736A (en) 1986-07-01
AU5849986A (en) 1986-12-18
NZ216485A (en) 1991-06-25
CA1285507C (en) 1991-07-02
FI90983B (fi) 1994-01-14
US4885166A (en) 1989-12-05
HUT41846A (en) 1987-05-28
DK168794B1 (da) 1994-06-13
SG25195G (en) 1995-08-18
JPH05308973A (ja) 1993-11-22
IL79085A0 (en) 1986-09-30
EP0205404B1 (de) 1992-07-15
IE861542L (en) 1986-12-11
HU203255B (en) 1991-06-28
NO175602B (no) 1994-07-25
JPH0655759B2 (ja) 1994-07-27
NO862313L (no) 1986-12-12
JPS626000A (ja) 1987-01-12
JPH0736757B2 (ja) 1995-04-26
EP0205404A3 (en) 1987-10-21
GR861497B (en) 1986-10-10
IE57865B1 (en) 1993-05-05
NO862313D0 (no) 1986-06-10
DK272986A (da) 1986-12-12
KR870000427A (ko) 1987-02-18
NO175602C (no) 1994-11-02
AU598196B2 (en) 1990-06-21
DE3685996D1 (de) 1992-08-20
FI862461A0 (fi) 1986-06-09
PT82736B (pt) 1988-12-15
US5071761A (en) 1991-12-10
EP0205404A2 (de) 1986-12-17
DE3685996T2 (de) 1993-01-14
DK272986D0 (da) 1986-06-10

Similar Documents

Publication Publication Date Title
ATE78262T1 (de) Hybrid-interferone.
DE3583521D1 (de) Antivirale verbindungen.
IT8124967A0 (it) Interferoni di leucociti umani ibridi.
FI863378A0 (fi) Rengoeringsfoerfarande av interferon.
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
FR2431507A1 (fr) 1-desamino-2-desoxy-2-epi-amino fortimicine b
EP0315637A4 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben.
DE3577713D1 (de) Thermoplastische, weichmacherhaltige polyvinylbutyralformmassen.
DE3575435D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.
NO861635L (no) Fremgangsmaate for fremstilling av rekombinert aaa-interferon.
NO894573D0 (no) Rekombinante interleukin-2 hybridproteiner.
ES8504795A1 (es) Un procedimiento para obtener 2,5-anhidro-3,4,6-tri-o-acil-d-alonselenocarboxamida
FI930024A0 (fi) Nya antivirala tetrahydroimidazo(1,4)benzodiazepin-2-(ti)oner
ATA551881A (de) Dreilagiger formkoerper, insbesondere blech, von hoher verschleissfestigkeit
SU939352A1 (ru) Двухмассный вибрационный конвейер
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
ATE98263T1 (de) Immunverstaerkung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time